BioCentury
ARTICLE | Financial News

Aveo proposes follow-on

January 17, 2013 1:31 AM UTC

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) said late Wednesday it is planning a follow-on underwritten by JPMorgan; RBC Capital Markets; and Canaccord. Aveo's Tivopath tivozanib is under FDA review to treat renal cell carcinoma (RCC), with a July 28 PDUFA date. The inhibitor of VEGF receptors 1, 2 and 3 is partnered with Astellas Pharma Inc. (Tokyo:4503), which has co-development and commercialization rights outside of Asia. Aveo has exclusive ex-Asian rights to tivozanib from Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151). ...